Web Stats Provided By Google Analytics

Wednesday, September 24, 2014

On eve of IPO, Civitas Therapeutics is acquired for $525M

On the eve of a planned $75 initial public offering, Chelsea biotech firm Civitas Therapeutics has been acquired by an Ardsley, NY-based biotech for $525 million. Acorda , which is developing treatments for multiple sclerosis and spinal cord injury treatments, will be buying worldwide rights to CVT-301, a Phase 3 inhaled drug delivery technology for controlling episodes of Parkinson's disease.

http://ift.tt/1xfbNNc

No comments:

Post a Comment

Popular Ardsley Roundup Posts